Eight Alzheimer's drugs in phase II clinical trials and 27 Alzheimer's drugs in phase III clinical trials are on track to launch within the next five years, according to an analysis conducted by ResearchersAgainstAlzheimer's, a global network of more than 450 researchers and part of the patient advocacy and lobby group UsAgainstAlzheimer's.
For the analysis, researchers examined drugmakers' Securities and Exchange Commission filings, company reports and media coverage, among other sources. They also conducted interviews with drug executives. In total, researchers identified 58 phase II drugs and 30 phase III drugs in development in 2017. The 2017 numbers mark an 18-percent increase of in-development phase II drugs and a 7 percent increase of in-development phase III drugs since 2016.
"The Alzheimer's disease pipeline, marred by decades of failures and underinvestment, is due for big victories," said George Vradenburg, UsAgainstAlzheimer's co-founder and chairman. "Thanks to growing investment from industry leaders, we remain cautiously optimistic that the current crop of late-stage Alzheimer's innovations will bring much-needed solutions to families in the near future."
Six phase III Alzheimer's drug trials are set to conclude before the end of the year.
More articles on supply chain:
Merck to build tech hub in Texas
5 drugmakers in the headlines
3 latest FDA approvals